Nanocarriers' Entry into the Cell: Relevance to Drug Delivery

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2009 Jun 6

PMID 19499185

Citations 338

Authors

Herve Hillaireau

Patrick Couvreur

Affiliations

Soon will be listed here.

Abstract

Nanocarriers offer unique possibilities to overcome cellular barriers in order to improve the delivery of various drugs and drug candidates, including the promising therapeutic biomacromolecules (i.e., nucleic acids, proteins). There are various mechanisms of nanocarrier cell internalization that are dramatically influenced by nanoparticles' physicochemical properties. Depending on the cellular uptake and intracellular trafficking, different pharmacological applications may be considered. This review will discuss these opportunities, starting with the phagocytosis pathway, which, being increasingly well characterized and understood, has allowed several successes in the treatment of certain cancers and infectious diseases. On the other hand, the non-phagocytic pathways encompass various complicated mechanisms, such as clathrin-mediated endocytosis, caveolae-mediated endocytosis and macropinocytosis, which are more challenging to control for pharmaceutical drug delivery applications. Nevertheless, various strategies are being actively investigated in order to tailor nanocarriers able to deliver anticancer agents, nucleic acids, proteins and peptides for therapeutic applications by these non-phagocytic routes.

Citing Articles

Major heme proteins hemoglobin and myoglobin with respect to their roles in oxidative stress - a brief review.

Sil R, Chakraborti A Front Chem. 2025; 13:1543455.

PMID: 40070406 PMC: 11893434. DOI: 10.3389/fchem.2025.1543455.

Preclinical evaluation of polymer encapsulated carbon-based nano and microparticles for sentinel lymph node tattooing.

Baselga M, Guemes A, Arruebo M, Yus C, Alejo T, Sebastian V Sci Rep. 2024; 14(1):29512.

PMID: 39604460 PMC: 11603039. DOI: 10.1038/s41598-024-80931-z.

Preparation of Glutathione-Responsive Paclitaxel Prodrug Based on Endogenous Molecule of L-Glutathione Oxidized for Cancer Therapy.

Duan X, Wang Q, Wang Y, Liu X, Lu M, Li Z Pharmaceutics. 2024; 16(9).

PMID: 39339214 PMC: 11435141. DOI: 10.3390/pharmaceutics16091178.

cRGD-Peptide Modified Covalent Organic Frameworks for Precision Chemotherapy in Triple-Negative Breast Cancer.

Benyettou F, Khair M, Prakasam T, Varghese S, Matouk Z, Alkaabi M ACS Appl Mater Interfaces. 2024; 16(42):56676-56695.

PMID: 39267454 PMC: 11503616. DOI: 10.1021/acsami.4c10812.

Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood-Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery.

Madadi A, Sohn M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204177 PMC: 11357388. DOI: 10.3390/ph17081070.

References

Rigotti A, Acton S, Krieger M . The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem. 1995; 270(27):16221-4. DOI: 10.1074/jbc.270.27.16221. View

Adler-Moore J, Proffitt R . AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002; 49 Suppl 1:21-30. DOI: 10.1093/jac/49.suppl_1.21. View

Donald P, Sirgel F, Venter A, Smit E, Parkin D, van de Wal B . The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J Antimicrob Chemother. 2001; 48(6):877-80. DOI: 10.1093/jac/48.6.877. View

Tsapis N, Bennett D, Jackson B, Weitz D, Edwards D . Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002; 99(19):12001-5. PMC: 129387. DOI: 10.1073/pnas.182233999. View

Salem I, Flasher D, Duzgunes N . Liposome-encapsulated antibiotics. Methods Enzymol. 2005; 391:261-91. DOI: 10.1016/S0076-6879(05)91015-X. View

Gregoriadis G . Liposomes in the therapy of lysosomal storage diseases. Nature. 1978; 275(5682):695-6. DOI: 10.1038/275695a0. View

Mayor S, Pagano R . Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007; 8(8):603-12. PMC: 7617177. DOI: 10.1038/nrm2216. View

Lambert G, Fattal E, Brehier A, Feger J, Couvreur P . Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. Biochimie. 1999; 80(12):969-76. DOI: 10.1016/s0300-9084(99)80002-9. View

Dvorak H, Nagy J, Dvorak J, Dvorak A . Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988; 133(1):95-109. PMC: 1880651. View

10.

Mao S, Germershaus O, Fischer D, Linn T, Schnepf R, Kissel T . Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm Res. 2005; 22(12):2058-68. DOI: 10.1007/s11095-005-8175-y. View

11.

Kim S, Jeong J, Chun K, Park T . Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir. 2005; 21(19):8852-7. DOI: 10.1021/la0502084. View

12.

Lee K, Hong K, Papahadjopoulos D . Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta. 1992; 1103(2):185-97. DOI: 10.1016/0005-2736(92)90086-2. View

13.

Sun X, Rossin R, Turner J, Becker M, Joralemon M, Welch M . An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules. 2005; 6(5):2541-54. PMC: 2533516. DOI: 10.1021/bm050260e. View

14.

Torrado J, Espada R, Ballesteros M, Torrado-Santiago S . Amphotericin B formulations and drug targeting. J Pharm Sci. 2007; 97(7):2405-25. DOI: 10.1002/jps.21179. View

15.

Maruyama K, Takahashi N, Tagawa T, Nagaike K, IWATSURU M . Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 1997; 413(1):177-80. DOI: 10.1016/s0014-5793(97)00905-8. View

16.

Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux J, Benoit J . Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A. 2006; 78(3):620-8. DOI: 10.1002/jbm.a.30711. View

17.

Fattal E, Bochot A . State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm. 2008; 364(2):237-48. DOI: 10.1016/j.ijpharm.2008.06.011. View

18.

Couvreur P, Tulkens P, Roland M, Trouet A, SPEISER P . Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett. 1977; 84(2):323-6. DOI: 10.1016/0014-5793(77)80717-5. View

19.

Nori A, Jensen K, Tijerina M, Kopeckova P, Kopecek J . Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug Chem. 2003; 14(1):44-50. DOI: 10.1021/bc0255900. View

20.

Christofidou-Solomidou M, Pietra G, Solomides C, Arguiris E, Harshaw D, FitzGerald G . Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs. Am J Physiol Lung Cell Mol Physiol. 2000; 278(4):L794-805. DOI: 10.1152/ajplung.2000.278.4.L794. View